gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ACONHealthcareMedical Labs

Aclarion, Inc. Common Stock (ACON)

$1.77+0.68%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$1.76▼ 77.52% in range
Nov 3, 2025Low $1.76 · High $8.17Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Aclarion closed at $1.77 on Nov 4, up 0.68%, within 0.7% of its 52-week closing low. Volume of 6.9K shares was 0.38× its 20-day average (below normal).

Split-adjusted performance: -22.6% over one month, -46.0% over six months, -77.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $25.21K, up 30.5% from a year earlier, with a net margin of -10899.5%.

Short interest was 24.6K shares at the Oct 15 settlement, down 49.7% from the prior report (0.9% of float, 1.1 days to cover).

Market cap$5.1M2.9M shares
Revenue · quarter$25.2K+30.5% YoY
Diluted EPS$-1.12—
P/E · TTM—P/S 61.0×
Net margin-10,899.5%Gross 32.9%
Dividend yieldNone
52-week range1.76 – 8.17−78.3% from high
Volume6.9K0.38× 20-day avg
Volatility · 60d69.1%Annualised
Short % of float0.9%1.1 days to cover
Net cash$16.3MCash $16.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −13.1%1M −22.6%3M −24.6%6M −46.0%YTD −61.5%1Y −77.4%3Y −100.0%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum14
Revenue growth67
Net margin5
Value (low P/E)—
Size9

Industry medians: 6-month return +36.5%, revenue growth +25.0%, net margin −4.0%, P/E 32.5×.

Short interest

Details →
Shares short24.6K−49.7% vs prior
Days to cover1.1Settled Oct 15
% of float0.9%
Short vol. 10d37.0%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ACONAclarion$1.77+0.68%−46.0%+30.5%−10899.5%—$5.1M
ADVBAdvanced Biomed$2.24+1.82%−67.0%—544.5%0.6$3.7MCompare
AMSAmerican Shared Hospital Services$1.24+0.81%−31.5%+19.2%−6.1%—$8.2MCompare
BGLCBioNexus Gene Lab$0.9400−1.05%−53.0%−96.6%−376.1%—$2.8MCompare
SERASera Prognostics$2.06+6.61%+13.7%+76.5%−30463.3%—$81.2MCompare
XGNExagen$8.53+2.30%+176.1%+15.9%−16.0%—$206.7MCompare
BDSXBiodesix$21.44+1.85%+42.9%+34.2%−27.1%—$226.2MCompare
FLGTFulgent Genetics$19.86+2.50%+33.1%+4.4%−34.6%—$546.3MCompare
CSTLCastle Biosciences$35.94+2.28%+45.2%+20.1%−2.0%—$1.10BCompare

News about Aclarion

All news →
Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026GlobeNewswire Inc. · Oct 20, 2026▲ PositiveAclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate EnrollmentGlobeNewswire Inc. · Oct 8, 2026NeutralAclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence GenerationGlobeNewswire Inc. · Jun 3, 2026▲ PositiveAclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker StudyGlobeNewswire Inc. · Jun 1, 2026▲ PositiveAclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of NociscanGlobeNewswire Inc. · Apr 28, 2026▲ Positive

Quick answers

What does Aclarion do?
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan.
What is ACON's market cap?
$5.11M, based on the Nov 4 close of $1.77.
Does Aclarion pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ACON is sold short?
24.6K shares, 0.9% of float, as of Oct 15, 2026.
What sector is ACON in?
Healthcare, in the Medical Labs industry.

About Aclarion

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.

HQ: Broomfield, CO11 employeesListed Apr 22, 2022aclarion.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology